SEO URLwww.firestrike.ai/deals/janux-therapeutics-bristol-myers-squibb-acquisition-2026
acquisitionAnnounced · Jan 22, 2026OncologySource · Community DiscussionsArticle · Factual
Bristol-Myers Squibb acquires Janux Therapeutics
David Najork · Founding Software Engineer
Published · Updated · 1 min read
Deal value
—
Target
Janux Therapeutics
NASDAQ: JANX · San Diego, California
Acquirer
Bristol-Myers Squibb
Collaboration
Status
Announced
Bristol-Myers Squibb agreed to acquire Janux Therapeutics. Reported deal value: Undisclosed. Status: Announced. Sector: Oncology. Target headquarters context: San Diego, California, United States.
This page summarizes publicly available information about the transaction as of 2026-01-22. Figures and status may change as filings and press coverage update.
Janux Therapeutics , Inc. announced on Thursday that it has entered a strategic collaboration with Bristol Myers Squibb to advance the development of a new tumor-activated therapy
Deal timeline
Announced
Jan 22, 2026 · newsable.asianetnews.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Oncology. Figures and status may change as sources update.
Sources: newsable.asianetnews.com · Primary article · FireStrike proprietary index